Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DCPHNASDAQ:LNTHNASDAQ:ROIVNASDAQ:RVMD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDCPHDeciphera Pharmaceuticals$25.59$25.59$9.90▼$25.61$2.21B0.191.29 million shs600 shsLNTHLantheus$81.86+0.5%$84.34$73.11▼$126.89$5.64B0.111.01 million shs960,447 shsROIVRoivant Sciences$11.27-1.1%$11.13$8.73▼$13.06$7.74B1.175.62 million shs6.44 million shsRVMDRevolution Medicines$36.79-0.3%$39.61$29.17▼$62.40$6.88B1.11.65 million shs2.59 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDCPHDeciphera Pharmaceuticals0.00%0.00%0.00%0.00%0.00%LNTHLantheus+0.45%+1.30%+8.41%-16.41%+1.96%ROIVRoivant Sciences-1.05%-2.00%+2.64%+14.42%+6.62%RVMDRevolution Medicines-0.33%-8.12%-7.98%+9.43%-5.20%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDCPHDeciphera PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ALNTHLantheus4.3887 of 5 stars3.51.00.04.22.02.51.9ROIVRoivant Sciences2.055 of 5 stars3.51.00.00.02.52.50.0RVMDRevolution Medicines4.4585 of 5 stars4.52.00.04.72.51.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDCPHDeciphera Pharmaceuticals 0.00N/AN/AN/ALNTHLantheus 3.00Buy$130.5059.42% UpsideROIVRoivant Sciences 3.00Buy$17.5055.28% UpsideRVMDRevolution Medicines 3.00Buy$67.5883.70% UpsideCurrent Analyst Ratings BreakdownLatest DCPH, ROIV, LNTH, and RVMD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/25/2025RVMDRevolution MedicinesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.006/24/2025RVMDRevolution MedicinesWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$67.00 ➝ $73.006/24/2025RVMDRevolution MedicinesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$57.006/23/2025LNTHLantheusB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$122.00 ➝ $109.006/18/2025ROIVRoivant SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.005/28/2025ROIVRoivant SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.005/14/2025RVMDRevolution MedicinesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$73.00 ➝ $72.005/8/2025LNTHLantheusTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$127.00 ➝ $117.005/8/2025RVMDRevolution MedicinesWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$67.005/8/2025RVMDRevolution MedicinesOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$70.00 ➝ $75.005/8/2025RVMDRevolution MedicinesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$87.00 ➝ $80.00(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDCPHDeciphera Pharmaceuticals$174.91M12.65N/AN/A$4.38 per share5.84LNTHLantheus$1.53B3.69$7.12 per share11.49$15.65 per share5.23ROIVRoivant Sciences$29.05M263.73N/AN/A$7.45 per share1.51RVMDRevolution Medicines$11.58M591.79N/AN/A$13.47 per share2.73Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDCPHDeciphera Pharmaceuticals-$194.94M-$2.21N/AN/AN/A-108.86%-52.42%-40.05%N/ALNTHLantheus$312.44M$3.5223.2612.97N/A16.55%36.99%20.55%7/30/2025 (Estimated)ROIVRoivant Sciences-$171.98M-$0.25N/AN/AN/A-225.71%-14.76%-13.69%8/6/2025 (Estimated)RVMDRevolution Medicines-$600.09M-$4.00N/AN/AN/AN/A-37.06%-32.84%8/6/2025 (Estimated)Latest DCPH, ROIV, LNTH, and RVMD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/29/2025Q4 2025ROIVRoivant Sciences-$0.16-$0.31-$0.15-$0.29$62.17 million$7.57 million5/7/2025Q1 2025LNTHLantheus$1.64$1.53-$0.11$1.02$377.37 million$372.76 million5/7/2025Q1 2025RVMDRevolution Medicines-$1.12-$1.13-$0.01-$1.13N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDCPHDeciphera PharmaceuticalsN/AN/AN/AN/AN/ALNTHLantheusN/AN/AN/AN/AN/AROIVRoivant SciencesN/AN/AN/AN/AN/ARVMDRevolution MedicinesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDCPHDeciphera PharmaceuticalsN/A4.193.94LNTHLantheus0.495.745.46ROIVRoivant SciencesN/A33.4733.47RVMDRevolution MedicinesN/A13.4613.46Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDCPHDeciphera Pharmaceuticals70.96%LNTHLantheus99.06%ROIVRoivant Sciences64.76%RVMDRevolution Medicines94.34%Insider OwnershipCompanyInsider OwnershipDCPHDeciphera Pharmaceuticals4.67%LNTHLantheus2.00%ROIVRoivant Sciences7.90%RVMDRevolution Medicines8.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDCPHDeciphera Pharmaceuticals30086.48 million82.44 millionOptionableLNTHLantheus70069.19 million67.80 millionOptionableROIVRoivant Sciences860679.81 million626.10 millionOptionableRVMDRevolution Medicines250186.27 million170.99 millionOptionableDCPH, ROIV, LNTH, and RVMD HeadlinesRecent News About These CompaniesRevolution Medicines and Summit Therapeutics Enter into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors with Ivonescimab in RAS Mutant TumorsJune 30 at 8:00 AM | globenewswire.comLunate Capital Ltd Invests $77.66 Million in Revolution Medicines, Inc. (NASDAQ:RVMD)June 29 at 7:38 AM | marketbeat.comBrokerages Set Revolution Medicines, Inc. (NASDAQ:RVMD) Target Price at $67.58June 29 at 2:17 AM | americanbankingnews.comQ3 EPS Estimate for Revolution Medicines Raised by AnalystJune 27, 2025 | marketbeat.comRevolution Medicines (NASDAQ:RVMD) Earns "Buy" Rating from GuggenheimJune 26, 2025 | americanbankingnews.comRevolution Medicines, Inc. (NASDAQ:RVMD) Given Average Recommendation of "Buy" by AnalystsJune 26, 2025 | marketbeat.comRevolution Medicines (NASDAQ:RVMD) Earns "Buy" Rating from Needham & Company LLCJune 26, 2025 | americanbankingnews.comRevolution Medicines (NASDAQ:RVMD) Given Outperform Rating at WedbushJune 26, 2025 | americanbankingnews.comRevolution Medicines' (RVMD) Buy Rating Reiterated at GuggenheimJune 25, 2025 | marketbeat.comWedbush Reiterates "Outperform" Rating for Revolution Medicines (NASDAQ:RVMD)June 24, 2025 | marketbeat.comRevolution Medicines' Daraxonrasib Receives FDA Breakthrough Therapy Designation for Metastatic Pancreatic Ductal Adenocarcinoma | NasdaqJune 24, 2025 | nasdaq.comNeedham & Company LLC Reiterates "Buy" Rating for Revolution Medicines (NASDAQ:RVMD)June 24, 2025 | marketbeat.comRevolution Medicines (NASDAQ:RVMD) Shares Gap Down - Here's What HappenedJune 24, 2025 | marketbeat.comRoyalty Pharma to pay up to $2 billion to Revolution Medicines for cancer drugJune 24, 2025 | reuters.comRevolution Medicines Enters Into $2 Billion Flexible Funding Agreement with Royalty Pharma to Support Global Development and Commercialization of RAS(ON) Inhibitor Portfolio for Patients with RAS-Addicted CancersJune 24, 2025 | globenewswire.comRevolution Medicines, Inc.: Revolution Medicines Announces FDA Breakthrough Therapy Designation for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer with KRAS ...June 23, 2025 | finanznachrichten.deRevolution Medicines Announces FDA Breakthrough Therapy Designation for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer with KRAS G12 MutationsJune 23, 2025 | globenewswire.comSG Americas Securities LLC Acquires 15,164 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD)June 22, 2025 | marketbeat.comRevolution Medicines: Positioning Itself To Capture One Of The Largest Cancer Targets In HistoryJune 19, 2025 | seekingalpha.comGAMMA Investing LLC Purchases 20,696 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD)June 18, 2025 | marketbeat.comHarbor Capital Advisors Inc. Acquires New Holdings in Revolution Medicines, Inc. (NASDAQ:RVMD)June 13, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDCPH, ROIV, LNTH, and RVMD Company DescriptionsDeciphera Pharmaceuticals NASDAQ:DCPHDeciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.Lantheus NASDAQ:LNTH$81.86 +0.37 (+0.45%) Closing price 06/30/2025 04:00 PM EasternExtended Trading$81.22 -0.64 (-0.78%) As of 09:27 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.Roivant Sciences NASDAQ:ROIV$11.27 -0.12 (-1.05%) Closing price 06/30/2025 04:00 PM EasternExtended Trading$11.34 +0.07 (+0.62%) As of 09:27 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.Revolution Medicines NASDAQ:RVMD$36.79 -0.12 (-0.33%) Closing price 06/30/2025 04:00 PM EasternExtended Trading$36.66 -0.13 (-0.34%) As of 09:25 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s $100M Nuclear OS Pact Boosts Bullish Case Joby Stock Soars as Piloted Flights in Dubai Signal a New Era Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500 S&P 500 All-Time Highs: 5 Catalysts Driving It Higher The Top Insider Sells From Q2: Buy, Sell, or Hold? 5 High-Yielding ETFs to Buy and Hold Forever Why BigBear.ai Could Rally 100% and Catch Palantir Soon Why McCormick Stock Could Soar After Durables Data Surprise Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
